The government set the Alzheimer drug’s price at ¥66,948 per 350-milligram vial. As a dip is required every month, it will cost a patient about ¥3.08 million per year. Treatment with donanemab will last up to 18 months.
Due to the high costs, the government will provide subsidies to cap patients’ out-of-pocket expenses. As a result, most of the costs will be shouldered by the government. The insurance coverage will start Nov. 20.
Donanemab became the second Alzheimer drug that targets causative deposited plaque in the brain to win the coverage after lecanemab, developed by Japanese drugmaker Eisai and its U.S. partner Biogen. Both drugs are designed to slow progression of the cognitive disorder.
A decade later, there would be some 26,000 users of donanemab, whose clinical application is expected to begin by the end of the year, experts said.
